Phillip A. Hsieh

474 total citations
16 papers, 339 citations indexed

About

Phillip A. Hsieh is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Phillip A. Hsieh has authored 16 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 10 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Phillip A. Hsieh's work include Multiple Myeloma Research and Treatments (13 papers), CAR-T cell therapy research (7 papers) and Protein Degradation and Inhibitors (5 papers). Phillip A. Hsieh is often cited by papers focused on Multiple Myeloma Research and Treatments (13 papers), CAR-T cell therapy research (7 papers) and Protein Degradation and Inhibitors (5 papers). Phillip A. Hsieh collaborates with scholars based in United States, Taiwan and China. Phillip A. Hsieh's co-authors include Kenneth Wen, Yu‐Tzu Tai, Shih‐Feng Cho, Kenneth C. Anderson, Liang Lin, Lijie Xing, Nikhil C. Munshi, Tengteng Yu, Yuyin Li and Jiye Liu and has published in prestigious journals such as Blood, Clinical Cancer Research and Leukemia.

In The Last Decade

Phillip A. Hsieh

16 papers receiving 338 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Phillip A. Hsieh United States 8 239 211 154 103 81 16 339
Gabriel N. Waterman United States 7 187 0.8× 178 0.8× 118 0.8× 60 0.6× 96 1.2× 8 310
Sabarinath Venniyil Radhakrishnan United States 12 219 0.9× 128 0.6× 119 0.8× 112 1.1× 39 0.5× 28 332
Tengteng Yu China 13 330 1.4× 340 1.6× 280 1.8× 142 1.4× 123 1.5× 44 555
Suzie Vardanyan United States 7 213 0.9× 223 1.1× 131 0.9× 47 0.5× 120 1.5× 20 322
YT Tai United States 6 247 1.0× 245 1.2× 366 2.4× 90 0.9× 95 1.2× 10 543
Alan Wilhelm United States 9 273 1.1× 104 0.5× 128 0.8× 47 0.5× 154 1.9× 22 388
Camilia Soof United States 10 154 0.6× 199 0.9× 106 0.7× 100 1.0× 99 1.2× 29 302
Turner Kufe United States 6 164 0.7× 128 0.6× 216 1.4× 148 1.4× 40 0.5× 7 368
Kristine A. Frerichs Netherlands 13 286 1.2× 287 1.4× 152 1.0× 136 1.3× 166 2.0× 19 452
Lauren Harvey United States 6 179 0.7× 112 0.5× 88 0.6× 45 0.4× 64 0.8× 8 258

Countries citing papers authored by Phillip A. Hsieh

Since Specialization
Citations

This map shows the geographic impact of Phillip A. Hsieh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip A. Hsieh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip A. Hsieh more than expected).

Fields of papers citing papers by Phillip A. Hsieh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip A. Hsieh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip A. Hsieh. The network helps show where Phillip A. Hsieh may publish in the future.

Co-authorship network of co-authors of Phillip A. Hsieh

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip A. Hsieh. A scholar is included among the top collaborators of Phillip A. Hsieh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip A. Hsieh. Phillip A. Hsieh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Xing, Lijie, Su Wang, Jiye Liu, et al.. (2021). BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clinical Cancer Research. 27(19). 5376–5388. 22 indexed citations
2.
Lin, Liang, Shih‐Feng Cho, Lijie Xing, et al.. (2020). Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 35(3). 752–763. 64 indexed citations
3.
Xing, Lijie, Liang Lin, Tengteng Yu, et al.. (2020). A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 34(8). 2150–2162. 50 indexed citations
4.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2020). The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Advances. 4(17). 4195–4207. 53 indexed citations
5.
Lin, Liang, Lijie Xing, Shih‐Feng Cho, et al.. (2019). Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma. Blood. 134(Supplement_1). 1811–1811. 2 indexed citations
6.
Xing, Lijie, Liang Lin, Tengteng Yu, et al.. (2019). Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma. Blood. 134(Supplement_1). 1817–1817. 9 indexed citations
7.
Lin, Liang, Lijie Xing, Shih‐Feng Cho, et al.. (2019). Preclinical evaluation of CD8+ Anti-BCMA mRNA CAR T-Cells for control of multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e169–e169. 2 indexed citations
8.
Xing, Lijie, Yuyin Li, Liang Lin, et al.. (2019). MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells. Blood. 134(Supplement_1). 3096–3096. 5 indexed citations
9.
Lin, Liang, Shih‐Feng Cho, Kenneth Wen, et al.. (2019). Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells. Blood. 134(Supplement_1). 3105–3105. 2 indexed citations
10.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2019). AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo. Blood. 134(Supplement_1). 135–135. 23 indexed citations
11.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2018). Anti-BCMA BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment. Blood. 132(Supplement 1). 592–592. 23 indexed citations
12.
Tai, Yu‐Tzu, Liang Lin, Lijie Xing, et al.. (2018). APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 33(2). 426–438. 66 indexed citations
13.
14.
Xing, Lijie, Jiye Liu, Liang Lin, et al.. (2018). APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma. Blood. 132(Supplement 1). 407–407. 2 indexed citations
15.
Yu, Tengteng, Lijie Xing, Liang Lin, et al.. (2018). An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma. Blood. 132(Supplement 1). 5617–5617. 5 indexed citations
16.
Lin, Liang, Lijie Xing, Chirag Acharya, et al.. (2017). CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo. Blood. 130. 3067–3067. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriel N. Waterman Breakdown of academic impact, for papers by Sabarinath Venniyil Radhakrishnan Breakdown of academic impact, for papers by Tengteng Yu Breakdown of academic impact, for papers by Suzie Vardanyan Breakdown of academic impact, for papers by YT Tai Breakdown of academic impact, for papers by Alan Wilhelm Breakdown of academic impact, for papers by Camilia Soof Breakdown of academic impact, for papers by Turner Kufe Breakdown of academic impact, for papers by Kristine A. Frerichs Breakdown of academic impact, for papers by Lauren Harvey
Rankless by CCL
2026